Legal Representation
Attorney
Douglas H. Siegel
USPTO Deadlines
Application History
24 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 2, 2010 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Aug 2, 2010 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Dec 10, 2009 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Dec 10, 2009 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 10, 2009 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 10, 2009 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jun 2, 2009 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 2, 2009 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jun 2, 2009 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Dec 30, 2008 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 7, 2008 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 17, 2008 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Aug 30, 2008 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Aug 29, 2008 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 25, 2008 | DMCC | I | DATA MODIFICATION COMPLETED | Loading... |
| Aug 22, 2008 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Aug 18, 2008 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 18, 2008 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 18, 2008 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 10, 2008 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 10, 2008 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 10, 2008 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 9, 2008 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 5, 2008 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations acting on cytoskeletal structure and dynamics for the treatment of cancer and neurodegenerative disease
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005